<DOC>
	<DOCNO>NCT00300976</DOCNO>
	<brief_summary>The objective study confirm superiority intensive therapy conventional therapy concern prevention incidence exacerbation vascular complication cause diabetes mellitus ( DM ) randomize control study patient type 2 DM .</brief_summary>
	<brief_title>The Japan Diabetes Optimal Integrated Treatment Study 3 Major Risk Factors Cardiovascular Diseases</brief_title>
	<detailed_description>The objective study confirm superiority intensive therapy conventional therapy concern prevention incidence exacerbation vascular complication cause diabetes mellitus randomize controlled study patient type 2 DM . The primary outcome measure occurrence myocardial infarction , coronary bypass surgery , percutaneous transluminal coronary angioplasty , stroke , carotid endarterectomy , percutaneous transluminal cerebral angioplasty , carotid artery stenting , death .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Subjects consider eligible 45 year old old young 70 year old study entry , type 2 diabetes meet `` ( 1 ) ( 2 ) '' `` ( 1 ) ( 3 ) '' describe . [ Note : Those meet three `` ( 1 ) , ( 2 ) ( 3 ) '' also consider eligible inclusion . ] ( 1 ) Glycemic control Those HbA1c 6.9 % great despite treatment three regimen give . Diet exercise therapy alone , Diet exercise therapy plus 1 oral antidiabetic drug , Diet exercise therapy plus , GI 1 oral antiantidiabetic drug ( 2 ) Blood pressure control Those follow casual blood pressure ( BP ) level measure outpatient basis , Systolic BP 140 mmHg diastolic BP 90 mmHg antihypertensive agent , Systolic BP 130 mmHg diastolic BP 80 mmHg 1 2 ARB , ACEI longacting CCB Those receive antihypertensive agent ARB , ACEI longacting CCB eligible study entry , exception receive agent purpose blood pressure lower . ( 3 ) Lipid metabolism Those follow fast lipid level lipidlowering agent LDLcholesterol , 120 mg/dL ( calculate use Friedewald formula ) Triglycerides , 150 mg/dL HDLcholesterol , &lt; 40 mg/dL Subjects receive 1 lipidlowering agent judge eligible study entry meet criterion . However , care need take ensure fibrates discontinue fibrate treatment start study assign intensive therapy arm . 1 . Those poorly control hypertension despite pharmacological therapy ( systolic BP 200 mmHg diastolic BP 120 mmHg ) 2 . Those insulin therapy 3 . Those nondiabetic renal disease 4 . Those type 1 diabetes due pathogenic mechanism associate type 2 diabetes strongly suspect 5 . Those tested antiGAD antibody*positive 6 . Those LDLcholesterol 200 mg/dL 7 . Those suspected secondary hypertension renal parenchymal hypertension 8 . Those suspected hereditary lipid disorder strong family history lipid metabolic disorder 9 . Those receive antihypertensive agent ARB , ACEI , longacting CCB , except receive agent purpose blood pressure lower 10 . Those receive 3 antihypertensive agent ( i.e. , ARB , ACEI , longacting CCB ) , except receive agent purpose blood pressure lower 11 . Those serious retinopathy proliferative retinopathy 12 . Renal failure ( serum Cr : 2.0 mg/dL men ; 1.5 mg/dL woman ) 13 . Those history cardiac failure cardiac failure 14 . Those pregnant potentially pregnant 15 . Those meet follow criterion BNP 100 pg/mL , Myocardial infarction , Angina pectoris ( history disease ) , History coronary artery bypass graft ( CABG ) , History percutaneous coronary angioplasty ( PTCA ) , Other cardiac disease , ECG find leave ventricular hyperplasia , Abnormal ECG finding ( exclude isolate extrasystole right bundle branch block [ RBBB ] ) 16 . Those judged physician charge ineligible study entry</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Blood glucose</keyword>
	<keyword>Blood pressure</keyword>
	<keyword>Lipids</keyword>
</DOC>